Tsunenori Kondo

List of Publications by Year
in descending order

126	2,526	236925 25	254184 43
papers	citations	h-index	g-index

127	127	127	2701
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prognostic Impact of Trial-Eligibility Criteria in Patients with Metastatic Renal Cell Carcinoma. Urologia Internationalis, 2022, 106, 368-375.	1.3	6
2	Efficacy and feasibility of robot-assisted partial nephrectomy for octogenarians: comparison with younger counterparts. Journal of Robotic Surgery, 2022, 16, 1165-1173.	1.8	4
3	Surgical outcomes for older patients with renal cell carcinoma and inferior vena cava thrombus. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 110.e11-110.e18.	1.6	2
4	Temporal study of renal volume losses in patients with robotic partial nephrectomies. Journal of Endourology, 2022, , .	2.1	0
5	C-reactive protein kinetics to predict recurrence of high-risk renal cell carcinoma after radical surgery. International Journal of Clinical Oncology, 2022, 27, 969-976.	2.2	2
6	Immune Checkpoint Inhibitor Combination Therapy for Renal Cell Carcinomas With Concomitant Inferior Vena Cava Thrombi. In Vivo, 2022, 36, 1030-1034.	1.3	11
7	â€œThrombusâ€firstâ€•or â€œthrombusâ€lastâ€•approach for surgical management of renal cell carcinoma with inferior vena cava thrombus. International Journal of Urology, 2022, , .	1.0	0
8	Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2Âyears of follow-up. Japanese Journal of Clinical Oncology, 2022, , .	1.3	0
9	Is tailored systemic therapy in renal cell carcinoma realistic?. Lancet Oncology, The, 2022, 23, 555-557.	10.7	1
10	New Longitudinal Component of the RENAL Nephrometry Score for Predicting the Operative Complexity in Transperitoneal Robot-Assisted Partial Nephrectomy. Journal of Endourology, 2022, 36, 762-769.	2.1	5
11	Association Between Anesthetic Technique and Survival After Radical Nephroureterectomy: A Propensity Score-matching Study. In Vivo, 2022, 36, 458-464.	1.3	2
12	Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era. Targeted Oncology, 2022, 17, 307-319.	3.6	4
13	Editorial Comment from Dr Ishihara et al. to Nomogram for predicting survival of renal cell carcinoma with tumor thrombus based on perioperative clinicopathological factors from a Chinese highâ€volume center. International Journal of Urology, 2022, 29, 993-994.	1.0	0
14	Comparisons of surgical outcomes between transperitoneal and retroperitoneal approaches in robot-assisted laparoscopic partial nephrectomy for lateral renal tumors: a propensity score-matched comparative analysis. Journal of Robotic Surgery, 2021, 15, 99-104.	1.8	20
15	Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy. Japanese Journal of Clinical Oncology, 2021, 51, 296-304.	1.3	4
16	Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. Japanese Journal of Clinical Oncology, 2021, 51, 646-653.	1.3	22
17	Predictive role of Î³-glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma. International Journal of Clinical Oncology, 2021, 26, 552-561.	2.2	7
18	Efficacy of nivolumab versus molecularâ€targeted therapy as secondâ€line therapy for metastatic renal cell carcinoma: Realâ€world data from two Japanese institutions. International Journal of Urology, 2021, 28, 99-106.	1.0	4

#	Article	IF	Citations
19	Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data. Japanese Journal of Clinical Oncology, 2021, 51, 793-801.	1.3	7
20	Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 77.e17-77.e25.	1.6	16
21	Editorial Comment to â€œEvaluating the Oncological Outcomes of Pure Laparoscopic Radical Nephroureterectomy Performed for Upper Tract Urothelial Carcinoma Patients: A Multicenter Cohort Study Adjusted by Propensity Score Matchingâ€. Annals of Surgical Oncology, 2021, 28, 27-28.	1.5	0
22	Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Marker of Nivolumab Monotherapy for Previously Treated Metastatic Renal Cell Carcinoma. In Vivo, 2021, 35, 2855-2862.	1.3	6
23	The Controlling Nutritional Status CONUT Score in Patients With Advanced Bladder Cancer After Radical Cystectomy. In Vivo, 2021, 35, 999-1006.	1.3	11
24	Therapeutic benefit of lymphadenectomy for older patients with urothelial carcinoma of the upper urinary tract: a propensity score matching study. Japanese Journal of Clinical Oncology, 2021, 51, 802-809.	1.3	3
25	Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. Clinical and Experimental Nephrology, 2021, 25, 674-682.	1.6	2
26	Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus. Japanese Journal of Clinical Oncology, 2021, 51, 819-825.	1.3	11
27	Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study. Targeted Oncology, 2021, 16, 493-502.	3.6	6
28	Limited impact of warm ischemic threshold for partial nephrectomy in the robotic surgery era: A propensity score matching study. International Journal of Urology, 2021, 28, 1219-1225.	1.0	4
29	Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study. Pathology, 2021, 53, 720-727.	0.6	8
30	Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma. In Vivo, 2021, 35, 3585-3589.	1.3	4
31	Editorial Comment to Trends and safety of robotâ€assisted partial nephrectomy during the initial 2â€year period after government approval in Japan: A nationwide database study from 2016 to 2018. International Journal of Urology, 2021, 28, 1272-1273.	1.0	0
32	Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. International Journal of Clinical Oncology, 2020, 25, 705-712.	2.2	3
33	The De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Prognosticator in Patients With End-stage Renal Diseaseâ€“associated Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 236-240.e1.	1.9	12
34	Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 526-532.	1.6	18
35	Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in endâ€stage renal disease. Cancer Science, 2020, 111, 4276-4287.	3.9	11
36	Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma. In Vivo, 2020, 34, 1541-1546.	1.3	10

#	Article	IF	Citations
37	Lower Incidence of Postoperative Acute Kidney Injury in Robot-Assisted Partial Nephrectomy Than in Open Partial Nephrectomy: A Propensity Score-Matched Study. Journal of Endourology, 2020, 34, 754-762.	2.1	13
38	Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 515-520.	1.6	15
39	Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy of a solitary kidney. International Journal of Clinical Oncology, 2020, 25, 1155-1162.	2.2	10
40	Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer. Japanese Journal of Clinical Oncology, 2020, 50, 933-939.	1.3	21
41	Mid-term outcome of transarterial embolization of renal artery pseudoaneurysm and arteriovenous fistula after partial nephrectomy screened by early postoperative contrast-enhanced CT. CVIR Endovascular, 2020, 3, 68.	1.1	4
42	Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. Targeted Oncology, 2019, 14, 453-463.	3.6	53
43	Negative Effect of Immediate Sunitinib Interruption on Survival in Patients With Metastatic Renal Cell Carcinoma. In Vivo, 2019, 33, 2153-2160.	1.3	6
44	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers. Clinical Genitourinary Cancer, 2019, 17, e772-e778.	1.9	15
45	Spatial and temporal responses of metastatic renal cell carcinoma lesions to sequential treatments over a 10â€year period. IJU Case Reports, 2019, 2, 37-42.	0.3	0
46	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. Medical Oncology, 2019, 36, 35.	2.5	4
47	RBM10â€“TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in breakâ€apart fluorescence inâ€situ hybridisation: study of 10 cases and a literature review. Histopathology, 2019, 75, 254-265.	2.9	29
48	Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 355.e21-355.e29.	1.6	64
49	Robotâ€assisted laparoscopic partial nephrectomy versus laparoscopic partial nephrectomy: A propensity scoreâ€matched comparative analysis of surgical outcomes and preserved renal parenchymal volume. International Journal of Urology, 2018, 25, 359-364.	1.0	21
50	Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy. International Journal of Clinical Oncology, 2018, 23, 559-567.	2.2	11
51	Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma. Medical Oncology, 2018, 35, 78.	2.5	15
52	Comparison of Kidney Function in the Early Postoperative Period in Transperitoneal Robot-Assisted Laparoscopic Partial Nephrectomy Between Anterior and Posterior Renal Tumors: A Propensity Score-Matched Study. Journal of Endourology, 2018, 32, 111-115.	2.1	10
53	Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study. Targeted Oncology, 2018, 13, 611-619.	3.6	3
54	Comparative study of lymph node dissection, and oncological outcomes of laparoscopic and open radical nephroureterectomy for patients with urothelial carcinoma of the upper urinary tract undergoing regional lymph node dissection. Japanese Journal of Clinical Oncology, 2018, 48, 1001-1011.	1.3	17

#	Article	IF	Citations
55	Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma. Targeted Oncology, 2018, 13, 745-755.	3.6	14
56	Acquired cystic diseaseâ€associated renal cell carcinoma is the most common subtype in longâ€term dialyzed patients: Central pathology results according to the 2016 WHO classification in a multiâ€institutional study. Pathology International, 2018, 68, 543-549.	1.3	37
57	Comparison of perioperative outcomes with or without renorrhaphy during open partial nephrectomy: A propensity score-matched analysis. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 467-474.	1.5	15
58	Prognostic Impact of the Components of Progressive Disease on Survival After First-Line Tyrosine Kinase Inhibitor Therapy for Metastatic Renal Cell Carcinoma. Targeted Oncology, 2018, 13, 379-387.	3.6	4
59	Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2018, 48, 860-863.	1.3	14
60	Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2018, 48, 667-672.	1.3	12
61	Impact of the Mayo Adhesive Probability Score on the Complexity of Robot-Assisted Partial Nephrectomy. Journal of Endourology, 2018, 32, 928-933.	2.1	23
62	Predictive value of inflammation-based prognostic scores in patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy. Oncotarget, 2018, 9, 14296-14305.	1.8	42
63	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World Journal of Urology, 2017, 35, 327-335.	2.2	26
64	Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2017, 47, 226-232.	1.3	8
65	Preoperative controlling nutritional status (CONUT) score as a novel predictive biomarker of survival in patients with localized urothelial carcinoma of the upper urinary tract treated with radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 539.e9-539.e16.	1.6	41
66	Robotâ€assisted laparoscopic versus open partial nephrectomy in patients with chronic kidney disease: A propensity scoreâ€matched comparative analysis of surgical outcomes. International Journal of Urology, 2017, 24, 505-510.	1.0	24
67	Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 540.e7-540.e12.	1.6	1
68	Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: AÂPropensity Score Matching Study. Clinical Genitourinary Cancer, 2017, 15, 598-604.	1.9	27
69	Evaluation of Firstâ€Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Singleâ€Center Experience With Four Cases. Therapeutic Apheresis and Dialysis, 2017, 21, 414-416.	0.9	0
70	Comparison of Surgical Outcomes Between Resection and Enucleation in Robot-Assisted Laparoscopic Partial Nephrectomy for Renal Tumors According to the Surface-Intermediate-Base Margin Score: A Propensity Score-Matched Study. Journal of Endourology, 2017, 31, 756-761.	2.1	20
71	Effect of Systemic Inflammation on Survival in Patients With Metastatic Renal Cell Carcinoma Receiving Second-line Molecular-targeted Therapy. Clinical Genitourinary Cancer, 2017, 15, 495-501.	1.9	22
72	Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma. International Journal of Clinical Oncology, 2017, 22, 767-773.	2.2	11

#	Article	IF	Citations
73	Molecular diagnosis of lymph node metastasis in patients with upper urinary tract cancer who underwent lymphadenectomy. International Journal of Urology, 2017, 24, 799-806.	1.0	3
74	Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 542.e1-542.e9.	1.6	21
75	Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer. International Journal of Clinical Oncology, 2017, 22, 145-152.	2.2	13
76	Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study. International Journal of Clinical Oncology, 2017, 22, 136-144.	2.2	42
77	Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy. International Journal of Clinical Oncology, 2017, 22, 126-135.	2.2	5
78	Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2017, 47, 1175-1181.	1.3	17
79	Treatment Overview. , 2017, , 177-207.		2
80	Rapid Progressive Disease After Nivolumab Therapy in Three Patients with Metastatic Renal Cell Carcinoma. In Vivo, 2017, 31, 769-771.	1.3	17
81	Treatment-related deterioration of renal function is associated with the antitumor efficacy of sunitinib in patients with metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 338.e1-338.e9.	1.6	9
82	Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment. Targeted Oncology, 2016, 11, 605-617.	3.6	66
83	A propensity score-matched comparison of surgical precision obtained by using volumetric analysis between robot-assisted laparoscopic and open partial nephrectomy for T1 renal cell carcinoma: a retrospective non-randomized observational study of initial outcomes. International Urology and Nephrology, 2016, 48, 1585-1591.	1.4	17
84	The magnitude of best tumor shrinkage during second-line targeted therapy affects progression-free survival but not overall survival in patients with metastatic renal cell carcinoma. Japanese Journal of Clinical Oncology, 2016, 46, 568-574.	1.3	8
85	The safety and validity of surgical resection for hemodialysis-dependent patients with renal cell carcinomas involving the inferior vena cava. International Cancer Conference Journal, 2016, 5, 136-139.	0.5	0
86	Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. International Journal of Clinical Oncology, 2016, 21, 126-132.	2.2	18
87	Early unclamping might reduce the risk of renal artery pseudoaneurysm after robotâ€assisted laparoscopic partial nephrectomy. International Journal of Urology, 2015, 22, 1096-1102.	1.0	54
88	Editorial Comment to Impact of smoking on the age at diagnosis of upper tract urothelial carcinoma: Subanalysis of the Japanese Urological Association multiâ€institutional national database. International Journal of Urology, 2015, 22, 1027-1028.	1.0	0
89	Solid-type RCC originating from native kidneys in renal transplant recipients should be monitored cautiously. Transplant International, 2015, 28, 813-819.	1.6	8
90	Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population. International Journal of Clinical Oncology, 2015, 20, 1035-1041.	2.2	18

#	Article	IF	Citations
91	Fat-poor angiomyolipoma with cyst-like changes mimicking a cystic renal cell carcinoma: a case report. World Journal of Surgical Oncology, 2015, 13, 251.	1.9	5
92	Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib. Japanese Journal of Clinical Oncology, 2015, 45, 274-280.	1.3	5
93	Early Postoperative Screening by Contrast-Enhanced CT and Prophylactic Embolization of Detected Pseudoaneurysms Prevents Delayed Hemorrhage after Partial Nephrectomy. Journal of Vascular and Interventional Radiology, 2015, 26, 950-957.	0.5	16
94	High preoperative C-reactive protein values predict poor survival in patients on chronic hemodialysis undergoing nephrectomy for renal cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 67.e9-67.e13.	1.6	22
95	Renal sinus exposure as an independent factor predicting asymptomatic unruptured pseudoaneurysm formation detected in the early postoperative period after minimally invasive partial nephrectomy. International Journal of Urology, 2015, 22, 356-361.	1.0	33
96	Therapeutic role of template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract. World Journal of Clinical Oncology, 2015, 6, 237.	2.3	18
97	The Role of Lymphadenectomy in the Management of Urothelial Carcinoma of the Upper Urinary Tract. , 2015, , 153-178.		0
98	Possible Role of Template-based Lymphadenectomy in Reducing the Risk of Regional Node Recurrence after Nephroureterectomy in Patients with Renal Pelvic Cancer. Japanese Journal of Clinical Oncology, 2014, 44, 1233-1238.	1.3	21
99	<scp>IJU</scp> this issue. International Journal of Urology, 2014, 21, 441-441.	1.0	24
100	Editorial Comment to Partial and radical nephrectomy provide comparable longâ€term cancer control for <scp>T</scp>1b renal cell carcinoma. International Journal of Urology, 2014, 21, 128-129.	1.0	1
101	Better recovery of kidney function in patients with de novo chronic kidney disease after partial nephrectomy compared with those with preâ€existing chronic kidney disease. International Journal of Urology, 2014, 21, 613-616.	1.0	8
102	Templateâ€based lymphadenectomy in urothelial carcinoma of the renal pelvis: A prospective study. International Journal of Urology, 2014, 21, 453-459.	1.0	48
103	Enhanced computed tomography after partial nephrectomy in early postoperative period to detect asymptomatic renal artery pseudoaneurysm. International Journal of Urology, 2014, 21, 880-885.	1.0	49
104	Superior Tolerability of Altered Dosing Schedule of Sunitinib with 2-Weeks-on and 1-Week-off in Patients with Metastatic Renal Cell Carcinoma--Comparison to Standard Dosing Schedule of 4-Weeks-on and 2-Weeks-off. Japanese Journal of Clinical Oncology, 2014, 44, 270-277.	1.3	83
105	Negative impact of papillary histological subtype in patients with renal cell carcinoma extending into the inferior vena cava: Singleâ€center experience. International Journal of Urology, 2013, 20, 1072-1077.	1.0	19
106	Role of lymphadenectomy in the management of urothelial carcinoma of the bladder and the upper urinary tract. International Journal of Urology, 2012, 19, 710-721.	1.0	50
107	Similar functional outcomes after partial nephrectomy for clinical T1b and T1a renal cell carcinoma. International Journal of Urology, 2012, 19, 980-986.	1.0	16
108	Decompressive surgery in combination with preoperative transcatheter arterial embolization: Successful improvement of ambulatory function in renal cell carcinoma patients with metastatic extradural spinal cord compression. International Journal of Urology, 2011, 18, 718-722.	1.0	8

#	Article	IF	Citations
109	Prognosis and characteristics of renal cell carcinoma in hemodialysis patients: Bilateral occurrence does not influence cancerâ€specific survival. International Journal of Urology, 2011, 18, 806-812.	1.0	8
110	The role of lymph node dissection in the management of urothelial carcinoma of the upper urinary tract. International Journal of Clinical Oncology, 2011, 16, 170-178.	2.2	24
111	Clinical Results and Pharmacokinetics of Sorafenib in Chronic Hemodialysis Patients with Metastatic Renal Cell Carcinoma in a Single Center. Japanese Journal of Clinical Oncology, 2011, 41, 647-655.	1.3	40
112	Contralateral metachronous tumor occurrence is more frequently associated with distant metastases or postoperative intrarenal recurrence in renal cell carcinoma patients. International Journal of Urology, 2010, 17, 615-622.	1.0	8
113	Templateâ€based lymphadenectomy in urothelial carcinoma of the upper urinary tract: Impact on patient survival. International Journal of Urology, 2010, 17, 848-854.	1.0	98
114	Presurgical Targeted Therapy with Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma: Clinical Results and Histopathological Therapeutic Effects. Japanese Journal of Clinical Oncology, 2010, 40, 1173-1179.	1.3	34
115	Minimal Effect of Cold Ischemia Time on Progression to Late-Stage Chronic Kidney Disease Observed Long Term After Partial Nephrectomy. Urology, 2008, 72, 1083-1088.	1.0	20
116	Primary Site and Incidence of Lymph Node Metastases in Urothelial Carcinoma of Upper Urinary Tract. Urology, 2007, 69, 265-269.	1.0	128
117	Impact of the Extent of Regional Lymphadenectomy on the Survival of Patients With Urothelial Carcinoma of the Upper Urinary Tract. Journal of Urology, 2007, 178, 1212-1217.	0.4	132
118	Successful testis preservation for bilateral testicular tumors with a new chemotherapyâ€based protocol: Initial results of three cases. International Journal of Urology, 2007, 14, 879-882.	1.0	17
119	Impact of the long-term duration of hemodialysis on the prognosis of dialysis patients with renal cell carcinoma. Nihon Toseki Igakkai Zasshi, 2007, 40, 643-647.	0.1	2
120	A case of granular cell tumor of the bladder successfully managed with extraperitoneal laparoscopic surgery. International Journal of Urology, 2006, 13, 827-828.	1.0	11
121	Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Science, 2006, 97, 780-786.	3.9	81
122	Spoke-wheel-like enhancement as an important imaging finding of chromophobe cell renal carcinoma: A retrospective analysis on computed tomography and magnetic resonance imaging studies. International Journal of Urology, 2004, 11, 817-824.	1.0	50
123	HIGH EXPRESSION OF CHEMOKINE GENE AS A FAVORABLE PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA. Journal of Urology, 2004, 171, 2171-2175.	0.4	86
124	Impact of arterial occlusion during partial nephrectomy on residual renal function: An evaluation with ^{99m} technetiumâ€dimercaptosuccinic acid scintigraphy. International Journal of Urology, 2002, 9, 435-440.	1.0	19
125	Interferon-Î³ Inducible Protein (IP-10) Expression Is Mediated by CD8+ T Cells and Is Regulated by CD4+ T Cells During the Elicitation of Contact Hypersensitivity. Journal of Investigative Dermatology, 1996, 107, 360-366.	0.7	55
126	INDUCTION OF CHEMOKINE GENE EXPRESSION DURING ALLOGENEIC SKIN GRAFT REJECTION1. Transplantation, 1996, 61, 1750-1757.	1.0	85